ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

COVID-19 mRNA vaccine (mNexspike)

mNEXSPIKE is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations. 

CHMP opinion 11 Dec 2025 → EU licence 12 Feb 2026 · Moderna Biotech Spain, S.L.

Research

Infectious diseases · Clin Infect Dis · 2026-10-28

In 833 adults aged ≥50, giving adjuvanted RSVPreF3 with an XBB.1.5 COVID-19 mRNA vaccine met non-inferiority for RSV-A and RSV-B titres vs sequential dosing but marginally missed it for SARS-CoV-2 (GMT ratio 1.31, 95% CI 1.13–1.51); safety was similar.

RCTn = 833
Bonten et al. Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority Trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.